PDF(Pubmed)
Abstract：
The overall cancer incidence and death toll have been increasing worldwide. However, the conventional therapies have some obvious limitations, such as non-specific targeting, systemic toxic effects, especially the multidrug resistance (MDR) of tumors, in which, autophagy plays a vital role. Therefore, there is an urgent need for new treatments to reduce adverse reactions, improve the treatment efficacy and expand their therapeutic indications more effectively and accurately. Combination therapy based on autophagy regulators is a very feasible and important method to overcome tumor resistance and sensitize anti-tumor drugs. However, the less improved efficacy, more systemic toxicity and other problems limit its clinical application. Nanotechnology provides a good way to overcome this limitation. Co-delivery of autophagy regulators combined with anti-tumor drugs through nanoplatforms provides a good therapeutic strategy for the treatment of tumors, especially drug-resistant tumors. Notably, the nanomaterials with autophagy regulatory properties have broad therapeutic prospects as carrier platforms, especially in adjuvant therapy. However, further research is still necessary to overcome the difficulties such as the safety, biocompatibility, and side effects of nanomedicine. In addition, clinical research is also indispensable to confirm its application in tumor treatment.
摘要：
全世界的癌症发病率和死亡人数一直在增加。然而,常规疗法有一些明显的局限性，例如非特异性靶向，全身性毒性作用，尤其是肿瘤的多药耐药性(MDR),其中，自噬起着至关重要的作用。因此,迫切需要新的治疗方法来减少不良反应，提高治疗效果,更有效、准确地扩大其治疗适应证。基于自噬调节因子的联合治疗是克服肿瘤耐药和提高抗肿瘤药物敏感性的一种非常可行和重要的方法。然而,功效改善越少，更多的全身毒性等问题限制了其临床应用。纳米技术提供了克服这一限制的好方法。自噬调节因子与抗肿瘤药物通过纳米平台共同递送,为肿瘤的治疗提供了良好的治疗策略,尤其是耐药肿瘤。值得注意的是,具有自噬调控特性的纳米材料作为载体平台具有广阔的治疗前景,尤其是辅助治疗。然而,仍然需要进一步的研究来克服诸如安全，生物相容性，和纳米医学的副作用。此外,临床研究对于证实其在肿瘤治疗中的应用也是必不可少的。
